Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Nov 24;6(37):40360-9.
doi: 10.18632/oncotarget.5465.

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Seung Tae Kim  1 , Won-Suk Lee  2 , Richard B Lanman  3 , Stefanie Mortimer  3 , Oliver A Zill  3 , Kyoung-Mee Kim  4   5 , Kee Taek Jang  5 , Seok-Hyung Kim  5 , Se Hoon Park  1 , Joon Oh Park  1   4 , Young Suk Park  1 , Ho Yeong Lim  1 , Helmy Eltoukhy  3 , Won Ki Kang  1 , Woo Yong Lee  6 , Hee-Cheol Kim  6 , Keunchil Park  1   4 , Jeeyun Lee  1   4 , AmirAli Talasaz  3
Affiliations
Clinical Trial

Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients

Seung Tae Kim et al. Oncotarget. .

Abstract

Sequencing of the mutant allele fraction of circulating cell-free DNA (cfDNA) derived from tumors is increasingly utilized to detect actionable genomic alterations in cancer. We conducted a prospective blinded study of a comprehensive cfDNA sequencing panel with 54 cancer genes. To evaluate the concordance between cfDNA and tumor DNA (tDNA), sequencing results were compared between cfDNA from plasma and genomic tumor DNA (tDNA). Utilizing next generation digital sequencing technology (DST), we profiled approximately 78,000 bases encoding 512 complete exons in the targeted genes in cfDNA from plasma. Seventy-five patients were prospectively enrolled between February 2013 and March 2014, including 61 metastatic cancer patients and 14 clinical stage II CRC patients with matched plasma and tissue samples. Using the 54-gene panel, we detected at least one somatic mutation in 44 of 61 tDNA (72.1%) and 29 of 44 (65.9%) cfDNA. The overall concordance rate of cfDNA to tDNA was 85.9%, when all detected mutations were considered. We collected serial cfDNAs during cetuximab-based treatment in 2 metastatic KRAS wild-type CRC patients, one with acquired resistance and one with primary resistance. We demonstrate newly emerged KRAS mutation in cfDNA 1.5 months before radiologic progression. Another patient had a newly emerged PIK3CA H1047R mutation on cfDNA analysis at progression during cetuximab/irinotecan chemotherapy with gradual increase in allele frequency from 0.8 to 2.1%. This blinded, prospective study of a cfDNA sequencing showed high concordance to tDNA suggesting that the DST approach may be used as a non-invasive biopsy-free alternative to conventional sequencing using tumor biopsy.

Trial registration: ClinicalTrials.gov NCT02067754.

Keywords: cell-free DNA (cfDNA); digital sequencing; genomic test.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

None declared except for RBL, SM, HE, AT who are employed by Guardant Health Inc.

Figures

Figure 1
Figure 1. STARD diagram
Figure 2
Figure 2. A. Mutational profiles (clinically significant variants, variants reported in COSMIC and other novel variants) detected in cfDNA for 61 advanced cancer patients with various tumor types and B. Details for genetic aberration analyzed in cfDNA and the concordance for comprehensive mutational profiles between tumor-tissue analysis and cfDNA
Figure 3
Figure 3. Patient monitoring with cfDNA during cetuximab-based treatment in metastatic colon cancer A. acquired resistance to cetuximab; B. primary resistance to cetuximab
See this image and copyright information in PMC

References

    1. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500. - PubMed
    1. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363:809–819. - PMC - PubMed
    1. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–1703. - PMC - PubMed
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765. - PubMed
    1. Cardarella S, Ortiz TM, Joshi VA, Butaney M, Jackman DM, Kwiatkowski DJ, Yeap BY, Janne PA, Lindeman NI, Johnson BE. The introduction of systematic genomic testing for patients with non-small-cell lung cancer. J Thorac Oncol. 2012;7:1767–1774. - PMC - PubMed

Publication types

MeSH terms

Associated data